Browsing: rare

Vertex PharmaceuticalsVRTX announced that it has agreed to acquire commercial-stage company Crinetics PharmaceuticalsCRNX. Per the terms, the large-cap biotech will acquire all outstanding shares of CRNX for $85 per share, valuing the deal at around $10 billion

Rare diseases, individually uncommon but collectively significant, affect fewer than five in 10,000 people per condition. However, with over 7,000 identified rare diseases, the combined impact is substantial – touching around 3.5 million people in the UK and more than 300 million worldwide. This scale underlines the critical need for global partnerships to accelerate both…

Expertise regarding these diagnoses is often limited among healthcare professionals. Furthermore, the lack of harmonised diagnostic coding in health information systems can result in delayed diagnosis, fragmented care, and suboptimal treatment. 

The UK has signed up to the European Rare Diseases Research Alliance (ERDERA), in a move that has been described as a “significant milestone of collaboration for UK science”